WCG Launches Neurostatus-eEDSS System
System incorporates Neurostatus Definitions booklet into the electronic data entry process to improve rater accuracy and consistency.
WCG has launched an enhanced digital version of the Neurostatus-Expanded Disability Status Scale (EDSS) to capture clinical trial data. Collaborating with Neurostatus-UHB Ltd., a University Hospital Basel (UHB) subsidiary led by CEO Marcus D'Souza, M.D. and Chief Operating Officer Evy Fricker, the e-EDSS aims to improve data quality for an MS clinical trial endpoint.
While this new system is designed to enhance the rater's data entry experience, it was built to provide better data quality through the implementation of the Neurostatus proprietary scoring algorithms and edit checks, supporting the rater with real-time feedback on data inconsistencies. A web-based data review process has been incorporated into the new e-EDSS system to facilitate faster review and oversight of data quality.
D'Souza said in a press release, "Data entry is extremely fast and easy, given its almost identical replication of the paper form with which researchers are already very familiar. This system also uniquely incorporates the Neurostatus Definitions booklet into the electronic data entry process, and we cannot wait to quantify the direct impact this has on rater accuracy and consistency."
Reference: WCG Collaborates With Leading Multiple Sclerosis KOL to Launch Neurostatus-eEDSS System/PRNewswire
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
